Cisplatin/Irinotecan With Concurrent Radiation for Inoperable NSCLC
A Phase II Study of Definitive Concurrent Radiation Therapy With Cisplatin and Irinotecan Chemotherapy in Locally Advanced In-operable Non-Small Cell Lung Cancer
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
North Carolina
-
Greenville, North Carolina, United States, 27834
- Leo W Jenkins Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histological or cytological documented NSCLC, including squamous cell carcinoma, adenocarcinoma, large cell carcinoma including large cell neuroendocrine carcinoma adenosquamous and sarcomatoid carcinomas.
- Patients with Pancoast tumors adjacent to a vertebral body are eligible as long as all gross disease can be encompassed in the radiation boost field. Pancoast tumor patients will be so-noted in the registry.
- Patients must be ≥ 18 years of age.
- Patients with Zubrod (ECOG) performance status ≤ 2.
- Adequate hematologic function defined as: ANC ≥ 1000/mm3, platelets ≥ 75,000/mm3, and hemoglobin ≥ 8 g/dL (prior to transfusions); adequate hepatic function defined as: total bilirubin ≤ 3.0 mg/dl, and adequate renal function defined as a serum creatinine level ≤ 2.0 mg/dl.
- Patients with weight loss ≤ 20% over the past 3 months.
- Patients with a pleural effusion that is proven cytologically negative or is too small to tap.
- Women of childbearing potential must agree to practice effective contraception throughout the study and for four weeks after completion of treatment.
Pretreatment evaluations required for eligibility include:
- A medical history, physical examination, and assessment of Zubrod performance status within 4 weeks prior to study entry.
- CBC with differential and platelet count, and laboratory profile must be completed within 4 weeks prior to study entry.
- CT scan of the chest or whole body PET (preferred), and a CT scan or MRI (preferred) of the brain within 4 weeks prior to study entry.
- For women of childbearing potential, a serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) must be performed within a week prior to the start of protocol treatment.
- Medical Oncology and Radiation Oncology consultation and approval.
- Patients must sign a study-specific consent form prior to study entry.
Exclusion Criteria:
- Small cell carcinomas or carcinoid histology.
- History of any malignancy in the past 2 years except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other in situ cancers.
- Prior systemic chemotherapy or radiotherapy that would interfere with delivery of treatment as outlined above as judged by the clinician.
- Cytologically malignant effusions.
- Radiographic evidence of metastatic disease.
- Active pulmonary infection not responsive to antimicrobial therapy.
- History of significant or symptomatic interstitial pneumonitis.
- Significant symptomatic cardiac disease, for example, unstable angina, uncompensated congestive heart failure, or uncontrolled cardiac ventricular arrhythmias.
- Patients with > grade 2 neuropathy.
- Women who are pregnant or breast feeding, as treatment involves unforeseeable risks to the participant, embryo, fetus, or nursing infant; women with a positive pregnancy test on enrollment or prior to study drug administration.
- Women of childbearing potential who are unwilling to practice effective contraception throughout the study and for four weeks after completion of treatment.
- Patients who currently are participating in other clinical trials and/or who have participated in other clinical trials in the previous 30 days.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: All enrolled patients
Induction Chemotherapy Cycle 1 - Irinotecan 65 mg/m2 and Cisplatin 30 mg/m2 on days 1 and 8 Concurrent Chemotherapy Cycles 2-4 - Irinotecan 65 mg/m2 and Cisplatin 30 mg/m2 on days 22 and 29, days 43 and 50, and days 64 and 71 along with radiation therapy of 60-70 Gy in 2 GY fractions on days 22 -71. |
Other Names:
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Estimate the median and three year survival rate of locally advanced NSCLC using the platinum doublet cisplatin and irinotecan
Time Frame: Three years after the last patient has completed treatement
|
Three years after the last patient has completed treatement
|
|
Estimate the progression-free survival
Time Frame: Three years after the last patient has completed treatement.
|
Three years after the last patient has completed treatement.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Compare the survival of patients treated with cisplatin/irinotecan with historical controls using cisplatin/etoposide.
Time Frame: Three years after the last patient has completed treatment.
|
Three years after the last patient has completed treatment.
|
|
Measure toxicities and compliance of patients on this regimen
Time Frame: Thirty days after completing treatment, averaging 100 days.
|
Thirty days after completing treatment, averaging 100 days.
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Paul Walker, MD, FACP, Brody School of Medicine at East Carolina University
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Antineoplastic Agents, Phytogenic
- Topoisomerase Inhibitors
- Topoisomerase I Inhibitors
- Irinotecan
- Camptothecin
Other Study ID Numbers
Other Study ID Numbers
- LJCC 2014-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.